Request Demo

Last update 23 Jan 2025

Peritoneal Fibrosis

Last update 23 Jan 2025

Basic Info

Synonyms

Fibroses, Peritoneal, Fibrosing Syndrome, Peritoneal, Fibrosing Syndromes, Peritoneal

+ [23]

Introduction

Disorder characterized by a wide range of structural changes in PERITONEUM, resulting from fibrogenic or inflammatory processes. Peritoneal fibrosis is a common complication in patients receiving PERITONEAL DIALYSIS and contributes to its gradual decrease in efficiency.

Drugs associated with Peritoneal Fibrosis

Alanylglutamine

Target

IL-17

Mechanism

IL-17 modulators [+1]

Active Org.

VUmc [+2]

Originator Org.

Fresenius Kabi AG

Active Indication

Glutamine Deficiency, Congenital [+2]

Inactive Indication

Dietary Supplement [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Apr 1995

GPCR antagonist(Viva Star)

Target

GPCR

Mechanism

GPCR antagonists

Active Org.

Viva Star Biosciences (Suzhou) Co., Ltd.

Originator Org.

Viva Star Biosciences (Suzhou) Co., Ltd.

Active Indication

Fibrosis [+5]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

GYY-4137

Target-

Mechanism

H2S donor

Active Org.

Zhejiang University

Originator Org.

National University of Singapore

Active Indication

Peritoneal Fibrosis

Inactive Indication

Cardiovascular Diseases

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Peritoneal Fibrosis

ACTRN12624000831583

/ Not yet recruitingNot ApplicableIIT

Indocyanine green for ureteric identification in complex gynaecology surgery: A single centered, randomised, double-blinded feasibility study in women planned to undergo complex gynaecological laparoscopic surgery

Start Date01 Aug 2024

Sponsor / Collaborator-

ChiCTR2300079292

/ SuspendedEarly Phase 1IIT

Expression of protein methyltransferase, deacetylase, deubiquitination enzyme, GPD2, pyrodeath and autophagy related proteins in human peritoneal tissue and peritoneal effluents

Start Date01 Jan 2024

Sponsor / Collaborator-

ChiCTR2300079318

/ SuspendedNot ApplicableIIT

Clinical study on early diagnosis and progression monitoring of peritoneal fibrosis using FAPI-PET imaging

Start Date01 Jan 2024

Sponsor / Collaborator-

100 Clinical Results associated with Peritoneal Fibrosis

100 Translational Medicine associated with Peritoneal Fibrosis

0 Patents (Medical) associated with Peritoneal Fibrosis

1,601

Literatures (Medical) associated with Peritoneal Fibrosis

01 Jan 2025·International Journal of Surgery Case Reports

Idiopathic encapsulating peritoneal sclerosis: A case report

Article

Author: Mehdi, Trabelsi Mohamed ; Neirouz, Kammoun ; Mohamed, Ben Hassine ; Faicel, Ben Salah ; Hichem, Jerraya ; Haifa, Ben Romdhane

INTRODUCTIONEncapsulating peritoneal sclerosis is a rare disease, characterized by subocclusive symptoms. Idiopathic forms could be challenging, as they are often mistaken for other conditions. We present a case mistaken for an internal hernia.CASE REPORTA 52-year-old male patient, who was complaining of abdominal pain and bloating for 6 months. He presented due to worsening of his symptoms. A CT scan was then performed evoking an internal hernia. Emergency surgery via laparoscopy revealed encapsulating peritoneal sclerosis with a cocoon-like fibrous tissue encasing the bowel. A conversion by a midline incision was performed for enterolysis and fibrous tissue resection.DISCUSSIONEncapsulating peritoneal sclerosis (EPS), is a rare disease. Because of the rigid capsule surrounding the loops, symptomatology includes recurrent occlusive symptoms. The incidence of this pathology is unknown. EPS is often associated with peritoneal dialysis(PD), infections, and systemic inflammatory disorders. Idiopathic cases, like in our patient, are often misdiagnosed pre-operatively. The treatment focuses on the management of the underlying cause if identified. Corticoids are proposed in inflammatory diseases while switching to hemodialysis or the use of tamoxifen and immunosuppressive therapies are proposed in case of PD. In case of failure of the conservative approaches or in case of emergency, a peritonectomy and enterolysis could be performed despite being at high risk of recurrence and mortality.CONCLUSIONWe aimed to describe a case misdiagnosed as an internal hernia to raise awareness among practitioners about this condition.

31 Dec 2024·Renal Failure

Caffeic acid phenethyl ester restores mitochondrial homeostasis against peritoneal fibrosis induced by peritoneal dialysis through the AMPK/SIRT1 pathway

Article

Author: Zeng, Ying ; Zhang, Wenwen ; Lu, Ying ; Gao, Luyan ; Hu, Ji ; Song, Kai

Increasing evidence suggests that peritoneal fibrosis induced by peritoneal dialysis (PD) is linked to oxidative stress. However, there are currently no effective interventions for peritoneal fibrosis. In the present study, we explored whether adding caffeic acid phenethyl ester (CAPE) to peritoneal dialysis fluid (PDF) improved peritoneal fibrosis caused by PD and explored the molecular mechanism. We established a peritoneal fibrosis model in Sprague-Dawley rats through intraperitoneal injection of PDF and lipopolysaccharide (LPS). Rats in the PD group showed increased peritoneal thickness, submesothelial collagen deposition, and the expression of TGFβ1 and α-SMA. Adding CAPE to PDF significantly inhibited PD-induced submesothelial thickening, reduced TGFβ1 and α-SMA expression, alleviated peritoneal fibrosis, and improved the peritoneal ultrafiltration function. In vitro, peritoneal mesothelial cells (PMCs) treated with PDF showed inhibition of the AMPK/SIRT1 pathway, mitochondrial membrane potential depolarization, overproduction of mitochondrial reactive oxygen species (ROS), decreased ATP synthesis, and induction of mesothelial-mesenchymal transition (MMT). CAPE activated the AMPK/SIRT1 pathway, thereby inhibiting mitochondrial membrane potential depolarization, reducing mitochondrial ROS generation, and maintaining ATP synthesis. However, the beneficial effects of CAPE were counteracted by an AMPK inhibitor and siSIRT1. Our results suggest that CAPE maintains mitochondrial homeostasis by upregulating the AMPK/SIRT1 pathway, which alleviates oxidative stress and MMT, thereby mitigating the damage to the peritoneal structure and function caused by PD. These findings suggest that adding CAPE to PDF may prevent and treat peritoneal fibrosis.

31 Dec 2024·Renal Failure

Efficacy of mesenchymal stem cells in the treatment of peritoneal fibrosis in animal models: a systematic review and meta-analysis

Review

Author: Liao, Chunling ; Zheng, Lingqian ; Lin, Yongda ; Xie, Yina ; Zhou, Tianbiao ; Chen, Wenmin ; Yao, Kaijin

BACKGROUNDPeritoneal fibrosis is a serious complication of long-term peritoneal dialysis, often resulting in functional deterioration and withdrawal from therapy. Mesenchymal stem cells (MSCs) have demonstrated immunomodulatory and antifibrotic effects in various models. This meta-analysis evaluated the efficacy of MSCs therapy in animal models of peritoneal fibrosis.METHODSA comprehensive search of PubMed, the Cochrane Library, Web of Science, and EMBASE was conducted for studies published up to April 27, 2024. Two independent reviewers (LQZ and WMC) screened studies for inclusion, extracted data, and analyzed outcomes using RevMan 5.3 and STATA 17.0.RESULTFifteen studies met the inclusion criteria. MSC therapy significantly reduced inflammatory cytokines, including IL-6, TGF-β (SMD = -1.79, 95% CI: -2.32, -1.25, p < 0.00001), and TNF-α (SMD = -1.57, 95% CI: -2.71, -0.44, p = 0.006) levels. Additionally, MSCs reduced submesothelial thickness (MD = -63.14, 95% CI: -78.52, -47.76, p < 0.00001), Collagen I and Collagen III levels. MSCs treatment also improved ultrafiltration capacity (MD = 1.21, 95% CI: 0.64, 1.77, p < 0.0001), D/D0 of glucose and E-cadherin levels. However, no significant differences were observed in VEGF, D/P of Na, D/P of BUN, D/P of protein, or glucose mass transfer between the MSCs treatment group and the control group.CONCLUSIONMSC therapy significantly improves peritoneal function and attenuates fibrotic and inflammatory responses in animal models. These findings highlight the potential of MSCs as a promising therapeutic strategy for managing peritoneal fibrosis in clinical settings.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Peritoneal Fibrosis

Basic Info

Related

Analysis